Focus: Zilia is a publicly-traded Brazilian biotech focused on ophthalmology devices for ocular biomarker assessment. The company operates at a modest scale with a single active job opening and limited commercial pipeline visibility.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
High-risk, early-stage opportunity suitable only for career builders willing to bet on unproven clinical and commercial strategy in a nascent biotech.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Zilia
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Zilia's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles